Latest Views & News

OptiBiotix Health – following recent developments, how does the valuation stack up?

By Tom Winnifrith & Steve Moore | Friday 1 April 2022

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Shares are now ‘ex-dividend’ for Optibiotix’s ‘ProBiotix Health’ business, which will be spun off onto the AQSE Growth Market – with an associated fundraise – at the end of this month. Additionally, SkinBioTherapeutics (SBTX), in which it has a 20.73% stake, has just announced half-year results – that the market did not like. So, how does the valuation stack up now?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Malcolm Stacey is Moving House

Monday »


Wood Group - a Buy (again)?



Video: Bubbles always implode

Tuesday »


Mondi – a recovery and income Buy?